ERBB2 and inflammatory breast carcinoma: A phase II study of lapatinib in HER2-positive inflammatory breast cancer showed that, phosphorylated HER3 predicted response to lapatinib and tumors coexpressing phosphorylated HER2 and HER3P were more likely to respond [27].